Physician profile
Hannah G Gallagher
NPI 1366125650
$2,457.92
in general payments reported to CMS, 2019-2025
24 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $260 · 2024: $1,033 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,457.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $646.73 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $295.96 | 2023-2025 | |
| Lilly USA, LLC | $238.77 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.53 | 2024-2025 | Jardiance |
| Pfizer INC. | $175.99 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $109.93 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $87.22 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $85.84 | 2024-2025 | Farxiga, Airsupra, Lokelma |
| Amgen INC. | $79.72 | 2024-2025 | Otezla, Repatha, Repatha |
| Sumitomo Pharma America, INC. | $79.36 | 2023-2024 | Gemtesa |
| Azurity Pharmaceuticals, INC. | $73.12 | 2023-2025 | Horizant, Edarbi, Horizant |
| Esperion Therapeutics, INC. | $67.76 | 2023-2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $49.82 | 2024-2025 | Voquezna |
| Alexion Pharmaceuticals, INC. | $48.94 | 2024-2025 | Ultomiris |
| Amneal Pharmaceuticals LLC | $45.91 | 2024-2025 | Unithroid |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $39.94 | 2023-2024 | Accrufer |
| Teva Pharmaceuticals USA, INC. | $23.39 | 2025 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $21.04 | 2025 | Rexulti |
| Lundbeck LLC | $19.86 | 2023 | Rexulti |
| Medtronic, INC. | $19.67 | 2025 | Inceptiv |
| Neurelis, INC. | $17.47 | 2023 | Valtoco |
| Dexcom, INC. | $17.38 | 2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $15.37 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $14.20 | 2025 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.